复发/难治性多发性骨髓瘤患者接受 CAR-T 细胞治疗的有效性和安全性评估：一项系统评价和 Meta 分析

Multiple myeloma (MM), the second most common hematologic malignancy, remains incurable, and its incidence is rising. Chimeric Antigen Receptor T-cell (CAR-T cell) therapy has emerged as a novel treatment, with the potential to improve the survival and quality of life of patients with relapsed/refractory multiple myeloma (rrMM).

In this systematic review and meta-analysis, conducted in accordance with PRISMA guidelines, we aim to provide a concise overview of the latest developments in CAR-T therapy, assess their potential implications for clinical practice, and evaluate their efficacy and safety outcomes based on the most up-to-date evidence. A literature search conducted from 1 January 2019 to 12 July 2023 on Medline/PubMed, Scopus, and Web of Science identified 2273 articles, of which 29 fulfilled the specified criteria for inclusion.

Our results offer robust evidence supporting CAR-T cell therapy's efficacy in rrMM patients, with an encouraging 83. 21% overall response rate (ORR). A generally safe profile was observed, with grade 3 cytokine release syndrome (CRS) at 7. 12% and grade 3 neurotoxicity at 1. 37%. A subgroup analysis revealed a significantly increased ORR in patients with fewer antimyeloma regimens, while grade 3 CRS was more common in those with a higher proportion of high-risk cytogenetics and prior exposure to BCMA therapy.